Barclays PLC Dyne Therapeutics, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 207,309 shares of DYN stock, worth $6.22 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

207,309

Previous 207,309 -0.0%

Holding current value

$6.22 Million

Previous $7.45 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$31.94 - $47.04 $4.1 Million - $6.03 Million	128,246 Added 162.21%	207,309 $7.45 Million
Q2 2024 Aug 14, 2024	SELL	$23.65 - $35.63 $116,097 - $174,907	-4,909 Reduced 5.85%	79,063 $2.79 Million
Q1 2024 May 15, 2024	SELL	$13.06 - $29.18 $906,089 - $2.02 Million	-69,379 Reduced 45.24%	83,972 $2.38 Million
Q4 2023 Feb 15, 2024	BUY	$6.62 - $13.64 $356,003 - $733,518	53,777 Added 54.01%	153,351 $2.04 Million
Q3 2023 Nov 07, 2023	BUY	$8.6 - $12.18 $151,385 - $214,404	17,603 Added 21.47%	99,574 $892,000
Q2 2023 Aug 03, 2023	BUY	$8.53 - $14.28 $425,501 - $712,329	49,883 Added 155.46%	81,971 $922,000
Q1 2023 May 04, 2023	BUY	$10.88 - $15.0 $85,353 - $117,675	7,845 Added 32.36%	32,088 $370,000
Q4 2022 Feb 13, 2023	BUY	$9.37 - $13.8 $67,126 - $98,863	7,164 Added 41.95%	24,243 $282,000
Q3 2022 Nov 03, 2022	SELL	$7.2 - $15.17 $449,424 - $946,911	-62,420 Reduced 78.52%	17,079 $217,000
Q2 2022 Aug 12, 2022	BUY	$4.36 - $10.5 $262,964 - $633,286	60,313 Added 314.36%	79,499 $547,000
Q1 2022 May 16, 2022	BUY	$6.52 - $12.27 $125,092 - $235,412	19,186 New	19,186 $185,000

Others Institutions Holding DYN

# of Institutions

210

Shares Held

102M

Call Options Held

234K

Put Options Held

238K

View Full List

About Dyne Therapeutics, Inc.

Ticker DYN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,765,400
Market Cap $1.55B
Description
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...

More about DYN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account